These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84. Two birds that exclude each other: the Renbök phenomenon. Mirmirani P J Invest Dermatol; 2015 Apr; 135(4):1180. PubMed ID: 25431848 [No Abstract] [Full Text] [Related]
85. Tofacitinib for polyarteritis nodosa: a tailored therapy. Rimar D; Alpert A; Starosvetsky E; Rosner I; Slobodin G; Rozenbaum M; Kaly L; Boulman N; Awisat A; Ginsberg S; Zilber K; Shen-Orr SS Ann Rheum Dis; 2016 Dec; 75(12):2214-2216. PubMed ID: 27558986 [No Abstract] [Full Text] [Related]
86. TOFACITINIB IN THE MANAGEMENT OF ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF AND ANTI-INTEGRIN THERAPIES. Teixeira FV; Damião AOMC; Kotze PG Arq Gastroenterol; 2018; 55(2):198-200. PubMed ID: 30043874 [TBL] [Abstract][Full Text] [Related]
87. Cost-effectiveness of Tofacitinib in the Treatment of Moderate to Severe Rheumatoid Arthritis in South Korea. Lee MY; Park SK; Park SY; Byun JH; Lee SM; Ko SK; Lee EK Clin Ther; 2015 Aug; 37(8):1662-76.e2. PubMed ID: 26243076 [TBL] [Abstract][Full Text] [Related]
88. Tofacitinab in renal transplantation. Zand MS Transplant Rev (Orlando); 2013 Jul; 27(3):85-9. PubMed ID: 23849222 [TBL] [Abstract][Full Text] [Related]
89. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors. Gladman D; Rigby W; Azevedo VF; Behrens F; Blanco R; Kaszuba A; Kudlacz E; Wang C; Menon S; Hendrikx T; Kanik KS N Engl J Med; 2017 Oct; 377(16):1525-1536. PubMed ID: 29045207 [TBL] [Abstract][Full Text] [Related]
90. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. Liu LY; Strassner JP; Refat MA; Harris JE; King BA J Am Acad Dermatol; 2017 Oct; 77(4):675-682.e1. PubMed ID: 28823882 [TBL] [Abstract][Full Text] [Related]
91. Application of the Itch Severity Score in patients with moderate-to-severe plaque psoriasis: Clinically important difference and responder analyses. Mamolo CM; Bushmakin AG; Cappelleri JC J Dermatolog Treat; 2015 Apr; 26(2):121-3. PubMed ID: 24716586 [TBL] [Abstract][Full Text] [Related]
92. Nail involvement in patients with moderate-to-severe alopecia areata treated with oral tofacitinib. Lee JS; Huh CH; Kwon O; Yoon HS; Cho S; Park HS J Dermatolog Treat; 2018 Dec; 29(8):819-822. PubMed ID: 29658800 [TBL] [Abstract][Full Text] [Related]
93. Tofacitinib: A Review in Psoriatic Arthritis. Paik J; Deeks ED Drugs; 2019 Apr; 79(6):655-663. PubMed ID: 30895473 [TBL] [Abstract][Full Text] [Related]
94. Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib. Bird P; Hall S; Nash P; Connell CA; Kwok K; Witcombe D; Thirunavukkarasu K RMD Open; 2019; 5(1):e000742. PubMed ID: 30886732 [TBL] [Abstract][Full Text] [Related]
95. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease. Sandborn WJ; Ghosh S; Panes J; Vranic I; Wang W; Niezychowski W; Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1485-93.e2. PubMed ID: 24480677 [TBL] [Abstract][Full Text] [Related]
96. Tofacitinib suppresses disease activity and febrile attacks in a patient with coexisting rheumatoid arthritis and familial Mediterranean fever. Gök K; Cengiz G; Erol K; Ozgocmen S Acta Reumatol Port; 2017; 42(1):88-90. PubMed ID: 28371574 [TBL] [Abstract][Full Text] [Related]
97. Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment. Strober B; Buonanno M; Clark JD; Kawabata T; Tan H; Wolk R; Valdez H; Langley RG; Harness J; Menter A; Papp K Br J Dermatol; 2013 Nov; 169(5):992-9. PubMed ID: 23855761 [TBL] [Abstract][Full Text] [Related]
99. Tofacitinib in paediatric dermatoses: a narrative review. Agarwal I; Panda M; Das A Clin Exp Dermatol; 2022 Jul; 47(7):1256-1264. PubMed ID: 35279865 [TBL] [Abstract][Full Text] [Related]
100. Successful treatment of refractory palmoplantar psoriasis in a psoriatic arthritis patient with the JAK inhibitor tofacitinib. Valor-Méndez L; Sticherling M; Kleyer A; Schett G Clin Exp Rheumatol; 2021; 39(1):228. PubMed ID: 32828149 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]